hPG80 at ASCO 2021 - Prolevcan study

Updated: Jul 5

Plasma hPG80 circulating prograstin levels in cancer patients in Nigeria: Prolevcan study.



#3029 Poster Session

Omolara A. Fatiregun, Dominique Joubert, Berengere Vire, Abigail Anni Frances Simon-Hart, Olaniyi Andrew Adekeye, Younes Mahi, Alexandre Prieur; Lagos State University Teaching Hospital, Ike- ja, Nigeria; ECS Progastrin, Prilly, Switzerland; EurBioDev, Montpellier, France; Bricon Global Consult Limited, Lagos, Nigeria; ECS-Progastrin, Prilly, Switzerland

Background: Progastrin is a tumor-promoting peptide which is detectable in the blood of patients with different cancers. hPG80 (circulating progastrin) is produced by cancer cells. Recently it was reported that hPG80 is detected in the blood of cancer patients, suggesting its potential utility for cancer detec- tion. In this Nigerian study, we assessed the performance of hPG80 in diagnosed cancer patients versus healthy volunteers.


Methods: Plasma samples of 50 patients with breast (n = 41) and colorectal (n = 9) cancer, aged from 26 to 70 years, were assayed for hPG80 levels with the DxPG80 kit from ECS-Progas- trin. The diagnostic performance (ROC AUC) of hPG80 was assessed compared to 50 healthy volunteers aged from 21 to 38 years.


Results: Plasma hPG80 levels were significantly higher in cancer patients compared to controls (median values: 4.59 pM (IQR: 2.02-8.27 pM) vs 1.37 pM (IQR: 0-3.11 pM), p < 0.0001). The median value of hPG80level was 3.96 pM (IQR: 1.61-7.89 pM) for breast cancers and 6.43 pM (IQR: 2.80-15.86 pM) for colorectal cancer patients. ROC AUC for all cancers, breast cancer and colorectal cancer were 0.75, 0.74 and 0.82 respectively. There was no correlation between hPG80 blood levels with age or CA15.3 levels.


Conclusions: Plasma hPG80 is a simple and relatively affordable blood test, it shows potential utility as a biomarker for cancer detection, monitoring and treatment as- sessment. Further prospective studies are needed to explore and confirm its potential. Research Spon- sor: None.




First Author: Omolara A. Fatiregun, MBBS

Meeting: 2021 ASCO Annual Meeting

Session Type: Poster Session

Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Subtrack: Circulating Biomarkers Abstract #: 3029

Citation:J Clin Oncol 39, 2021 (suppl 15; abstr 3029)

DOI:10.1200/JCO.2021.39.15_suppl.3029




2021_ASCO_Poster_ECS PROGASTRIN_Nigeria
.pdf
Download PDF • 278KB